Evofem Biosciences (NASDAQ:EVFM) reported quarterly sales of $4.30 million which beat the analyst consensus estimate of $4.15 million by 3.61 percent. This is a 289.14 percent increase over sales of $1.10 million the same period last year.
Cytokinetics Outlines Go-To-Market Strategy For Omecamtiv Mecarbil And Provides Updates On Cardiovascular Pipeline At Today’s Analyst & Investor Day
Cytokinetics, Incorporated (NASDAQ:CYTK) plans to outline the company’s go-to-market strategy for omecamtiv mecarbil in the United States, and present updates on the company’s advancing cardiovascular
